Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.60 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | NR2E3 | Q9Y5X4 | 1/20 | 0.56 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | HTR7 | P34969 | 1/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22864356 | 0.83 | KDM4E (0.60) | KDM4EPOLBALDH1A1L3MBTL1HTT | |
| SCHEMBL15630613 | 0.83 | KDM4E (0.60) | KDM4EPOLBALDH1A1L3MBTL1HTT | |
| SCHEMBL10219911 | 0.83 | KDM4E (0.60) | KDM4EPOLBALDH1A1L3MBTL1HTT | |
| SCHEMBL5888051 | 0.83 | KDM4E (0.60) | KDM4EPOLBALDH1A1L3MBTL1HTT | |
| SCHEMBL14973024 | 0.83 | KDM4E (0.60) | KDM4EPOLBALDH1A1L3MBTL1HTT | |
| Hydrochloric Acid SCHEMBL5887944 | 0.81 | KDM4E (0.58) | KDM4EPOLBALDH1A1L3MBTL1HTT | |
| Ammonia Solution, Strong SCHEMBL5888116 | 0.81 | KDM4E (0.58) | KDM4EPOLBALDH1A1L3MBTL1HTT | |
| SCHEMBL7365515 | 0.81 | KDM4E (0.71) | KDM4EPOLBALDH1A1L3MBTL1HTT | |
| SCHEMBL9558198 | 0.80 | MEN1 (0.59) | KDM4EALDH1A1L3MBTL1GAATSHR | |
| SCHEMBL13827637 | 0.80 | MEN1 (0.61) | KDM4EPOLBALDH1A1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3275870-B1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2020-02-05 | — | — | EP | disclosed |
| EP-3275870-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | Gilead Sciences, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| EP-2707361-B1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | GILEAD SCIENCES INC (US) | 2017-08-23 | — | — | EP | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682998-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2016-12-15 | — | — | US | disclosed |
| US-9403782-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9403782-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2016-08-02 | — | — | US | disclosed |
| US-9115096-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-9115096-B2 | Fused heterocyclic compounds as ion channel modulators | GILEAD SCIENCES, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| WO-2012154760-A1 | FUSED HETEROCYCLIC COMPOUNDS AS SODIUM CHANNEL MODULATORS | GILEAD SCIENCES, INC. (US) | 2012-11-15 | — | — | WO | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD SCIENCES, INC. | 2012-11-15 | — | — | US | disclosed |
| US-7125995-B2 | Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (PARS) | BAYER AKTIENGESELLSCHAFT (DE) | 2006-10-24 | — | — | US | disclosed |
| US-20050075347-A1 | Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (pars) | BAYER AKTIENGESELLSCHAFT (DE) | 2005-04-07 | — | — | US | disclosed |
| EP-1339699-A1 | SUBSTITUTED AMIDOALKYL URACILS AND THE USE THEREOF | Bayer Aktiengesellschaft (DE) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002040455-A1 | SUBSTITUTED AMIDOALKYL URACILS AND THEIR USE AS INHIBITORS OF THE POLY(ADP-RIBOSE) SYNTHETASE (PARS) | BAYER AKTIENGESELLSCHAFT (DE) | 2002-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289493-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | KDM4E 1666/4885POLB 4763/4885ALDH1A1 1702/4885 |
| US-20160362421-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, CACNA1A, KCNH2 | KDM4E 1666/4885POLB 4763/4885ALDH1A1 1702/4885 |
| US-20050075347-A1 | Substituted amidoalkyl uracils and their use as inhibitors of the poly(adp-ribose) synthetase (pars) | UNG, UMPS, PARP1 | KDM4E 4082/4885POLB 208/4885ALDH1A1 447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.